Skip to main content
TipRanks
Go Ultimate75% OFF

Sanofi (SNYNF) Q3 2026 Earnings Report

393 Followers

SNYNF Q3 2026 EPS Results

Actual EPS
$3.93
Consensus EPS
$3.08
Beat/Miss
Beat by +$0.84
One Year Ago EPS
$3.22

SNYNF Q3 2026 Revenue Results

Actual Revenue
―
Expected Revenue
$15.05B
Beat/Miss
―
YoY Revenue Growth
―

Earnings Announcement Details

Quarter
Q3 2026
Date
10/30/2026
Time
Before Open
Conference Call
Friday, October 30, 2026
SNYNF Upcoming Earnings

Sanofi's next earnings date is estimated for January 28, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

SNYNF Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Oct 30, 2026|% Change Since:15.73%|
Earnings Call Sentiment|Positive

The call was strongly positive overall. Sanofi reported robust Q3 sales and earnings growth, upgraded 2026 guidance, delivered double-digit growth in Dupixent and rare diseases, expanded its Regeneron alliance and outlined plans to improve R&D productivity. These strengths were partly offset by vaccine phasing, expected moderation in Dupixent growth, upcoming loss-of-exclusivity planning, portfolio and reimbursement headwinds, and acknowledged gaps in pipeline size and productivity.

Company Guidance

Sanofi upgraded 2026 guidance to sales growth at a low teens percentage, which usually means a range of 13%-15%, and business EPS growth at a mid-teen percentage, which usually means between 15% and 17%; vaccine sales are expected to be down by a low single-digit percentage for the full year. For 2027, the company is not providing formal guidance, but expects demand-driven growth, pricing to return to its historical pattern with a slightly negative pricing contribution to global sales growth, and legacy-portfolio transactions to reduce sales by around EUR 1.3 billion; it expects cost base growth at a lower level than sales, BOI to increase in absolute value and BOI margin, and profitable growth each and every single year between now and 2030. Sanofi is very confident it can reach EUR 25 billion of Dupixent sales by 2030, expects total revenue at group level to be impacted only moderately by Dupixent's LOE, and will focus on preserving earnings and cash flow before accelerating earnings growth.

  • Strong Q3 Sales GrowthQ3 total sales reached EUR 14.4 billion, up 14.3% versus last year, or 14% on the financial review. Underlying group sales growth, excluding more one-off items, was estimated at around 12%, with more than 85% of growth described as sustainable and demand-driven.
  • Upgraded 2026 GuidanceSanofi upgraded its 2026 guidance and now expects sales to grow at a low teens percentage, usually meaning 13%-15%, and business EPS to grow at a mid-teen percentage, usually meaning 15%-17%.
  • Improved Profitability and Operating LeverageGross margin improved by 2.1 percentage points, operating expenses were basically stable, BOI increased by 19.7%, BOI margin expanded by 1.9 percentage points, and business EPS grew by 19.6%. The margin improvement was driven by favorable product mix, pricing effects and operating leverage.
  • Dupixent Reaches EUR 5.7 Billion in Quarterly SalesDupixent sales reached EUR 5.7 billion in Q3, surpassing EUR 5 billion for the second consecutive quarter. More than 1.5 million patients are currently under treatment globally, with growth primarily driven by demand across major indications and geographies.
  • Dupixent Leadership and Long-Term TargetDupixent remains the number one prescribed biologic among key U.S. prescriber groups. Sanofi confirmed confidence in reaching EUR 25 billion of Dupixent sales by 2030 at constant exchange rates, while stating that demand growth is expected to continue.
  • New Launch Portfolio Continues to Diversify GrowthSales from newly launched medicines reached approximately EUR 2.2 billion in Q3, up 19.2%, and now represent roughly 15% of total company sales. Pharma launches grew over 31%, driven mainly by ALTUVIIIO, Ayvakit and Rezurock.
  • Rare Diseases Deliver Double-Digit GrowthThe rare disease portfolio reached EUR 1.9 billion in sales, up 12.6%. Growth was supported by Ayvakit, ALTUVIIIO, Wayrilz, Cablivi and Qfitlia, while Myqorzo, Anxu and Redemplo became available to Chinese patients.
  • Vaccine Franchise Shows ResilienceThe vaccines franchise declined 7% in Q3, better than the previously indicated potential low-to-mid-teens decline, due to more favorable buying patterns for Beyfortus late in the quarter. Heplisav-B grew 60% on a pro forma basis to EUR 125 million, and full-year vaccine sales are expected to decline by a low single-digit percentage.
  • Expanded Regeneron AllianceSanofi expanded its Regeneron alliance to gain access to four next-generation long-acting monoclonal antibodies targeting type 2 inflammation. The lead anti-IL-13 is already in phase I for atopic dermatitis, with potential dosing every three to six months, and registrational studies are expected to start in late 2027 or early 2028.
  • Potential Follow-On Immunology PortfolioThe expanded Regeneron alliance includes an anti-IL-4 receptor alpha antibody with potential to succeed Dupixent, an anti-IL-4 antibody for combination use, and a bispecific IL-4/IL-13 antibody. The other three assets are expected to enter phase I studies in 2027.
  • Strategic Focus on Three Therapeutic AreasSanofi confirmed immunology, rare diseases and vaccines as its three focus areas, where it sees robust growth opportunities and potential for differentiation. The majority of R&D spending and external innovation capital is intended to be allocated to these areas.
  • Business Development and M&A CapacitySanofi plans to use business development and M&A to secure growth, with a focus on late-stage and commercial medicines and disciplined bolt-on acquisitions. Management stated that its strong cash flow, balance sheet and low leverage provide access to external financing while retaining a strong investment-grade credit rating.
  • Cost Discipline and Cash Flow PrioritiesManagement reported strong cost discipline, including R&D prioritization, and expects cost growth to remain below sales growth. Sanofi aims to increase BOI in absolute value and BOI margin every year between now and 2030, while preserving earnings and cash flow through Dupixent's loss of exclusivity.
  • Long-Term Dividend Track RecordSanofi confirmed its commitment to its dividend policy, citing 31 consecutive years of dividend increases in absolute euro value.
  • R&D Transformation and AI InvestmentSanofi is reshaping R&D through sharper portfolio focus, technical reviews, adaptive study designs, increased talent density, greater use of AI and expanded access to external innovation. The company intends to deploy integrated AI agents company-wide and use AI across target identification, screening, candidate design and data-driven development decisions.
  • Pipeline and Research Capacity PlansThe pipeline comprises 61 development projects across pharma and vaccines, including 36 new molecules. Sanofi has approximately 2,000 colleagues across pharma and vaccines research and aims to start 12-15 first-in-human studies each year while maintaining its quality standards.
  • Balanced Internal and External Innovation ModelSanofi is targeting a 50/50 internal and external sourcing split, increasing contribution from China and pursuing upper-quartile speed and cost performance. The company intends to use China's drug discovery capabilities and translational speed to generate more molecules and proof-of-concept data.
  • Positive Regulatory and Clinical ProgressSanofi received the Ayvakit 50 mg U.S. label expansion in indolent systemic mastocytosis and MenQuadfi approval in the EU for meningococcal disease from six weeks of age. Teizeild was accepted for EU review in stage two Type 1 diabetes in children aged one to seven, while Beyfortus received priority review in China and SP0289 received EU PRIME designation for pandemic H5 influenza.
  • Selected Pipeline Assets Show PotentialManagement described efdoralprin alfa as addressing a population with poor standard of care and potentially offering best-in-disease convenience and efficacy. Frexalimab is being studied across multiple sclerosis, Type 1 diabetes and transplant, while duvakitug showed strong phase II efficacy in IBD and is being developed with a subcutaneous option.
  • Future Clinical MilestonesExpected future readouts include phase II data for lunsekimig in high-risk asthma and brivekimig in hidradenitis suppurativa, followed by phase III readouts for riliprubart in CIDP, pneumococcal and yellow fever vaccines, duvakitug in ulcerative colitis, Wayrilz life-cycle indications and frexalimab in multiple sclerosis.

SNYNF Earnings History

SNYNF earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Jan 28, 20272026 (Q4)1.89-1.69――
Oct 30, 20262026 (Q3)3.083.933.2221.99% (+0.71)
Jul 30, 20262026 (Q2)2.102.311.7631.45% (+0.55)
Apr 23, 20262026 (Q1)1.982.081.5336.23% (+0.55)
Jan 29, 20262025 (Q4)1.601.691.4516.79% (+0.24)
Oct 24, 20252025 (Q3)2.983.223.161.75% (+0.06)
Jul 31, 20252025 (Q2)1.811.761.91-8.09% (-0.15)
Apr 24, 20252025 (Q1)1.861.531.97-22.47% (-0.44)
Jan 30, 20252024 (Q4)1.501.451.84-21.08% (-0.39)
Oct 25, 20242024 (Q3)2.753.162.8212.16% (+0.34)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed